Pharmacodynamic evaluation of clopidogrel reloading vs. switching to prasugrel or ticagrelor in clopidogrel resistant Indian patients

Sandeep Khasa, Roopali Khanna, Fauzia Ashfaq, Pravin K. Goel
{"title":"Pharmacodynamic evaluation of clopidogrel reloading vs. switching to prasugrel or ticagrelor in clopidogrel resistant Indian patients","authors":"Sandeep Khasa,&nbsp;Roopali Khanna,&nbsp;Fauzia Ashfaq,&nbsp;Pravin K. Goel","doi":"10.1016/j.ctrsc.2015.10.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To compare the pharmacodynamic effects of clopidogrel reloading vs. switching to prasugrel or ticagrelor in high on treatment platelet reactivity (HTPR) patients undergoing percutaneous coronary intervention (PCI).</p></div><div><h3>Methods</h3><p>Prospective, single-centre study wherein consecutive patients undergoing nonemergent PCI showing HTPR on 600<!--> <!-->mg clopidogrel loading were randomized to either clopidogrel reloading (300<!--> <!-->mg load, 75<!--> <!-->mg OD) or prasugrel (60<!--> <!-->mg load, 10<!--> <!-->mg OD-in patients<!--> <!-->&gt;<!--> <!-->60<!--> <!-->kg) or ticagrelor (180<!--> <!-->mg load, 90<!--> <!-->mg BD). HTPR is defined as maximum platelet aggregation (MPA)<!--> <!-->&gt;<!--> <!-->46% assessed by 5<!--> <!-->μmol/L adenosine diphosphate light transmission aggregometry (ADP-LTA) assay after more than 6<!--> <!-->h of clopidogrel loading. Platelet function were assessed at baseline, 6<!--> <!-->h or more after clopidogrel loading, 2<!--> <!-->h after reloading, day 1 and day 30 post-PCI.</p></div><div><h3>Results</h3><p>107 patients enrolled in the study, 32 (29.9%) were found to have HTPR. 10 (9.3%) patients were reloaded with clopidogrel, 10 (9.3%) with prasugrel and 12 (11.2%) with ticagrelor. Mean MPA in clopidogrel, prasugrel and ticagrelor reloaded patients was 42.6<!--> <!-->±<!--> <!-->12.5%, 15.8<!--> <!-->±<!--> <!-->8.6% and 14.6<!--> <!-->±<!--> <!-->7.2% respectively at 2<!--> <!-->h after reloading and was 43.7<!--> <!-->±<!--> <!-->13.5%, 15.4<!--> <!-->±<!--> <!-->5.6% and 12.6<!--> <!-->±<!--> <!-->4.6% on day 1 post-PCI. The MPA significantly reduced in prasugrel and ticagrelor cases and not in clopidogrel, also prasugrel and ticagrelor had almost similar MPA after the reload. There was no patient with continued HTPR with ticagrelor or prasugrel while 50% (5/10) of clopidogrel reloaded patients had HTPR. The pharmacodynamic efficacy of maintenance with prasugrel or ticagrelor was better than clopidogrel (MPA at day 30 post-PCI; 15<!--> <!-->±<!--> <!-->9.7%, 13.9<!--> <!-->±<!--> <!-->5.1% and 50.4<!--> <!-->±<!--> <!-->13.1% respectively).</p></div><div><h3>Conclusion</h3><p>In patients undergoing PCI exhibiting HTPR after clopidogrel loading, ticagrelor or prasugrel reloading produced improved platelet inhibition which was better than clopidogrel reload and this effect was sustained during maintenance phase.</p></div>","PeriodicalId":91232,"journal":{"name":"Clinical trials and regulatory science in cardiology","volume":"13 ","pages":"Pages 14-20"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrsc.2015.10.007","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical trials and regulatory science in cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405587515300214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objectives

To compare the pharmacodynamic effects of clopidogrel reloading vs. switching to prasugrel or ticagrelor in high on treatment platelet reactivity (HTPR) patients undergoing percutaneous coronary intervention (PCI).

Methods

Prospective, single-centre study wherein consecutive patients undergoing nonemergent PCI showing HTPR on 600 mg clopidogrel loading were randomized to either clopidogrel reloading (300 mg load, 75 mg OD) or prasugrel (60 mg load, 10 mg OD-in patients > 60 kg) or ticagrelor (180 mg load, 90 mg BD). HTPR is defined as maximum platelet aggregation (MPA) > 46% assessed by 5 μmol/L adenosine diphosphate light transmission aggregometry (ADP-LTA) assay after more than 6 h of clopidogrel loading. Platelet function were assessed at baseline, 6 h or more after clopidogrel loading, 2 h after reloading, day 1 and day 30 post-PCI.

Results

107 patients enrolled in the study, 32 (29.9%) were found to have HTPR. 10 (9.3%) patients were reloaded with clopidogrel, 10 (9.3%) with prasugrel and 12 (11.2%) with ticagrelor. Mean MPA in clopidogrel, prasugrel and ticagrelor reloaded patients was 42.6 ± 12.5%, 15.8 ± 8.6% and 14.6 ± 7.2% respectively at 2 h after reloading and was 43.7 ± 13.5%, 15.4 ± 5.6% and 12.6 ± 4.6% on day 1 post-PCI. The MPA significantly reduced in prasugrel and ticagrelor cases and not in clopidogrel, also prasugrel and ticagrelor had almost similar MPA after the reload. There was no patient with continued HTPR with ticagrelor or prasugrel while 50% (5/10) of clopidogrel reloaded patients had HTPR. The pharmacodynamic efficacy of maintenance with prasugrel or ticagrelor was better than clopidogrel (MPA at day 30 post-PCI; 15 ± 9.7%, 13.9 ± 5.1% and 50.4 ± 13.1% respectively).

Conclusion

In patients undergoing PCI exhibiting HTPR after clopidogrel loading, ticagrelor or prasugrel reloading produced improved platelet inhibition which was better than clopidogrel reload and this effect was sustained during maintenance phase.

在氯吡格雷耐药的印度患者中,氯吡格雷再负荷与改用普拉格雷或替格瑞洛的药效学评价
目的比较经皮冠状动脉介入治疗(PCI)高血小板反应性(HTPR)患者重开氯吡格雷与改用普拉格雷或替格瑞洛的药效学效果。方法前瞻性单中心研究,连续接受非紧急PCI治疗的患者在600 mg氯吡格雷负荷下出现HTPR,随机分为氯吡格雷重新负荷(负荷300 mg, OD 75 mg)或普拉格雷(负荷60 mg, OD 10 mg)。60公斤)或替格瑞洛(负荷180毫克,每日90毫克)。HTPR定义为最大血小板聚集量(MPA) >经5 μmol/L二磷酸腺苷光透射聚类法(ADP-LTA)测定,氯吡格雷加载6 h以上,46%。在基线、氯吡格雷加载后6小时或更长时间、重新加载后2小时、pci后第1天和第30天评估血小板功能。结果纳入研究的107例患者中,32例(29.9%)发现HTPR。10例(9.3%)患者重新服用氯吡格雷,10例(9.3%)重新服用普拉格雷,12例(11.2%)重新服用替格瑞洛。氯吡格雷、普拉格雷和替格瑞再负荷患者的平均MPA在再负荷2 h时分别为42.6±12.5%、15.8±8.6%和14.6±7.2%,在pci术后第1天分别为43.7±13.5%、15.4±5.6%和12.6±4.6%。MPA在普拉格雷和替卡格雷组显著降低,而在氯吡格雷组无显著降低,而且普拉格雷和替卡格雷在重新加载后的MPA几乎相同。没有患者使用替格瑞或普拉格雷继续HTPR,而50%(5/10)的氯吡格雷重装患者发生HTPR。pci术后第30天,普拉格雷或替格瑞维持的药效学效果优于氯吡格雷(MPA);15±9.7%,分别为13.9±5.1%和50.4±13.1%)。结论在氯吡格雷负荷后出现HTPR的PCI患者中,替格瑞或普拉格雷负荷后对血小板的抑制效果优于氯吡格雷负荷,且这种效果在维持期持续。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信